BlueCross BlueShield of Tennessee Medical Policy Manual



25682-0001-XX - Soliris 300 MG/30ML SOLN (ALEXION PHARMACEUTICALS)


Eculizumab, a recombinant monoclonal antibody, binds to the complement protein C5 and inhibits its cleavage to C5a and C5b, preventing the generation of terminal complement complex C5b-9. The complement system of proteins, which is part of the immune system, destroys abnormal red blood cells. Eculizumab prevents destruction of red blood cells that are deficient in terminal complement inhibitors.







(Doses should be administered at the following intervals or within two days of these time points)

Paroxysmal nocturnal hemoglobinuria

Loading dose:

600mg every 7 days for the first 4 weeks, followed by 900mg for the fifth dose 7 days later and then 900mg every 14 days thereafter (initial loading dose requires a total of 3,300mg over 5 weeks)


Maintenance dose:

900 mg every 14 days

Atypical hemolytic uremic syndrome

Loading dose:

900mg every 7 days for the first 4 weeks, followed by 1,200mg for the fifth dose 7 days later and then 1,200mg every 14 days thereafter (initial loading dose requires a total of 4,800mg over 5 weeks)


Maintenance dose:

1200 mg every 14 days

Generalized Myasthenia Gravis (gMG)

Loading dose:

900 mg intravenously every 7 days for the first 4 weeks, followed by 1,200 mg intravenously for the fifth dose 7 days later


Maintenance dose:

1200 mg intravenously every 14 days

Dose Adjustment for aHUS (adult and pediatric patients) and gMG (adult patients) In Case of Plasmapheresis, Plasma Exchange or Fresh Frozen Plasma Infusion

Type of Plasma Exchange

Most Recent Eculizumab Dose

Supplemental Eculizumab With Each Plasma Intervention

Timing of Supplemental Eculizumab Dose

Plasmapheresis or plasma exchange (PE)

300 mg

300 mg per each plasmapheresis or PE

Within 60 minutes after each plasmapheresis or PE

≥ 600 mg

600 mg per each plasmapheresis or PE

Fresh frozen plasma infusion (FFP)

≥300 mg

300 mg per each infusion of FFP

60 minutes prior to each infusion of FFP


Coverage will be provided for twelve months for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) and may be renewed.

For Generalized Myasthenia Gravis (gMG), initial coverage will be provided for 6 months and may be renewed annually thereafter.

Refer to DOSAGE LIMITS below


BlueCross BlueShield of Tennessee’s Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.


We develop Medical Policies to provide guidance to Members and Providers.  This Medical Policy relates only to the services or supplies described in it.  The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy.  For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed.  If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.


For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).


Centers for Disease Control and Prevention. (2015, June). Morbidity and Mortality Weekly Report. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. Retrieved February 23, 2016 from

Laurence, J., Haller, H., Mannucci, P. M., Nangaku, M., Praga, M., Rodriguez de Cordoba, S. (2016). Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clinical Advances in Hematology and Oncology, 14 Suppl, 11(11), 2-15. Abstract retrieved March 13, 2018 from PubMed database.

Lexi-Comp Online. (2019, February). AHFS DI. Eculizumab. Retrieved March 7, 2019 from Lexi-Comp Online with AHFS.

MICROMEDEX Healthcare Series. Drugdex Drug Evaluations. (2019, January). Eculizumab. Retrieved March 7, 2019 from MICROMEDEX Healthcare Series.

Noris, M., Bresin, E., Mele, C., Remuzzi, G. (2007, March, updated 2016, June). Genetic Atypical Hemolytic-Uremic Syndrome. In: Adam, M. P., Ardinger, H. H., Pagon, R.A., et al., eds., GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Retrieved October 29, 2018 from

Parker, C. J. (2016, December). American Society of Hematology Education Program. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematology. v 2016(1); 2016 Dec 2; 2016(1), 208–216. Retrieved October 29, 2018 from

U. S. Food and Drug Administration. (2018, July). Center for Drug Evaluation and Research. Soliris® (eculizumab). Retrieved March 7, 2019 from




Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.



Maximum billable units per dose and over time by indication as a Medical Benefit; 1 billable unit = 10 mg





60 billable units Days 1, 8, 15, & 22; then 90 billable units Day 29

90 billable units every 14 days


90 billable units Days 1, 8, 15, & 22; then 120 billable units Day 29

120 billable units every 14 days